By Melissa Lipman ( May 3, 2011, 8:01 PM EDT) -- The number of so-called pay-for-delay deals between name-brand pharmaceutical companies and their generics competitors jumped by 60 percent in 2010, covering nearly two dozen drugs with $9.3 billion in U.S. sales, the Federal Trade Commission said Tuesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.